Oklahoma Supreme Court throws out $465 million opioid verdict against Johnson & Johnson
![Johnson & Johnson](https://cdn.mos.cms.futurecdn.net/LteunDXgrjcqEbw9sCcT48-415-80.jpg)
The Oklahoma Supreme Court on Tuesday overturned a $465 million judgement against Johnson & Johnson for its role in marketing, selling, and distributing opioids in the state. The 5-1 ruling found that Cleveland County District Judge Thad Balkman and state prosecutors had incorrectly used public nuisance laws to find Johnson & Johnson culpable in 2019.
"In reaching this decision, we do not minimize the severity of the harm that thousands of Oklahoma citizens have suffered because of opioids," the Oklahoma Supreme Court majority wrote in its ruling. "However grave the problem of opioid addiction is in Oklahoma, public nuisance law does not provide a remedy for this harm." The lone dissenter said the ruling should have been sent back to the lower court.
This is the second blow against the use of public nuisance laws against companies involved in the sale and distribution of opioids; a California judge tentatively ruled last week that several large counties had not proved opioid companies had violated public nuisance laws because they had failed to show that deceptive marketing had increased prescription abuse. Public nuisance laws are being used against opioid companies across the U.S. as states and local governments try to get restitution for an opioid crisis blamed for more than 500,000 deaths in 20 years.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Johnson & Johnson praised the Oklahoma ruling while state Attorney General John O'Connor said he was "disappointed" the Supreme Court had voided "a huge victory for Oklahoma citizens and their families who have been ravaged by opioids." He said his office will explore its options.
Are these two rulings against opioid flooding as a public nuisance "outlier opinions or are they trendsetters?" Elizabeth Burch, a University of Georgia law professor, told The Washington Post. "I think it's too early to be able to tell right now." There's a lot more opioid litigation on the horizon, she added, so "there's a lot that remains to be seen.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Is British history something to be proud of?
Talking Point A sharp fall in the number of people praising our past might not be a bad thing
By Elizabeth Carr-Ellis, The Week UK Published
-
Slow Horses, series four: 'swaggering' spy thriller returns
The Week Recommends Gary Oldman is 'impeccable' in one of the 'most consistent' shows on TV
By Ellie O'Mahoney, The Week UK Published
-
The UK's scams and fraud epidemic
The Explainer Record numbers are complaining they've fallen victim to online fraudsters
By Elizabeth Carr-Ellis, The Week UK Published
-
Scottish drug deaths: what's gone wrong?
The Explainer The latest figures show an increase in drug misuse deaths in Scotland
By Richard Windsor, The Week UK Published
-
Mushroom edibles are tripping up users
the explainer The psychedelics can sometimes have questionable components
By Devika Rao, The Week US Published
-
Rapamycin: the popular drug for longevity among biohackers
Under the Radar Living longer may be getting easier
By Devika Rao, The Week US Published
-
Pharmaceutical companies are warning of a rise in knockoff drugs
Under the Radar The World Health Organization is also urging consumers to be cautious
By Justin Klawans, The Week US Published
-
FDA panel rejects ecstasy to treat PTSD
Speed Read It cited flawed study data and the potential for abuse
By Peter Weber, The Week US Published
-
The push to ban decaf coffee
Under the radar Going caffeine-free can be risky
By Devika Rao, The Week US Published
-
US overdose deaths fell in 2023, still topped 100k
Speed Read New CDC data shows drug overdose deaths dropped for the first time in five years
By Peter Weber, The Week US Published
-
What reclassifying cannabis could change
The Explainer The Biden administration's move to change marijuana from a Schedule I narcotic to Schedule III could reshape the pot landscape even if it doesn't mean full federal legalization
By Rafi Schwartz, The Week US Published